TS-003675 — The IP is pioneering chimeric antigen receptor (CAR) technology to target Nucleolin (NCL) expressing T cells, and it has the ability to pinpoint NCL, an untapped antigen in cancer immunotherapy, for CAR-T cell targeting. By crafting CARs designed to target NCL and expressing them on T cells’ surface, this technology showcases promising anti-tumor activity against a spectrum of cancer types. At its current conceptual stage, proof-of-concept experiments have demonstrated successful targeting of breast cancers. Further endeavors are planned to validate the efficacy and specificity of CAR-T cells against numerous other cancers through meticulous in vitro and in vivo assays. Its innovative approach in targeting NCL broadens the horizons of cancer treatment, potentially diversifying the therapeutic options available to patients. The adaptable nature of CAR-T cells enables the targeting of various cancers, including breast, lung, brain cancer, myeloid, and lymphoid leukemia, among others.

TS-003674 — The IP focuses on the development of chimeric antigen receptor (CAR) targeting Nucleolin (NCL) expressing natural killer (NK) cells, offering a novel approach to cancer treatment. It has the ability to target NCL, a novel antigen in cancer immunotherapy that has not been previously utilized as a target for CAR-NK cells. By designing CARs targeting NCL and expressing them on the surface of NK cells, this technology demonstrates promising antitumor activity against various cancer types. The stage of development for this IP is currently conceptual, with proof-of-concept experiments demonstrating successful targeting of breast cancers. Further work is planned to verify the efficacy and specificity of CAR-NK cells against multiple other cancers through in vitro and in vivo assays. Its novelty in targeting NCL opens up new possibilities for cancer treatment, potentially expanding the repertoire of available therapies for patients. Additionally, the versatility of CAR-NK cells allows for targeting a wide range of cancers, including breast, lung, brain cancer, myeloid, and lymphoid leukemia, among others.